Adjunct bromocriptine treatment as palliation for prostate cancer: experimental and clinical evaluation.
Bromocriptine, a potent antiprolactin, in conjunction with low dose polyestradiolphosphate or cyproterone acetate resulted in a response rate of 28 out of 42 patients. The longest response with pain free and physical as well as sexual, full activity was 15 months until relapse occurred. There was a clear cut prevention of gynecomaesia in 11 out of 13 patients. This is a second report on treatment for prostatic cancer with bromocriptine.
D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D006728:Hormones / Q000097:blood; D006801:Humans; D008297:Male; D010146:Pain / Q000188:drug therapy; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D006728:Hormones; D001971:Bromocriptine